| 3.87 0.14 (3.75%) | 07-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.67 | 1-year : | 5.45 |
| Resists | First : | 4 | Second : | 4.67 |
| Pivot price | 3.79 |
|||
| Supports | First : | 3.74 | Second : | 3.57 |
| MAs | MA(5) : | 3.8  |
MA(20) : | 3.77 |
| MA(100) : | 3.11 |
MA(250) : | 2.38 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 54.6 |
D(3) : | 53.2 |
| RSI | RSI(14): 55.3 | |||
| 52-week | High : | 4.01 | Low : | 1.19 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ICAD ] has closed below upper band by 21.9%. Bollinger Bands are 70.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 36 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.88 - 3.9 | 3.9 - 3.91 |
| Low: | 3.82 - 3.84 | 3.84 - 3.86 |
| Close: | 3.83 - 3.87 | 3.87 - 3.91 |
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.
Mon, 10 Nov 2025
Does iCAD Inc. qualify in momentum factor screening - 2025 Institutional Moves & AI Powered Buy and Sell Recommendations - newser.com
Mon, 10 Nov 2025
Is iCAD Inc. stock a contrarian buy - Portfolio Risk Summary & Community Driven Trade Alerts - newser.com
Mon, 10 Nov 2025
Is iCAD Inc. stock a contrarian buy - Quarterly Profit Report & Fast Entry and Exit Trade Plans - newser.com
Fri, 18 Jul 2025
RadNet finalizes $103M acquisition of breast AI vendor iCAD amid legal opposition - Radiology Business
Fri, 18 Jul 2025
DeepHealth completes iCAD acquisition for breast cancer AI tools - healthcare-in-europe.com
Thu, 17 Jul 2025
RadNet’s Wholly-Owned Subsidiary, DeepHealth, Completes Acquisition of iCAD - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 27 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 5.5 (%) |
| Held by Institutions | 31.4 (%) |
| Shares Short | 270 (K) |
| Shares Short P.Month | 397 (K) |
| EPS | -0.19 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.12 |
| Profit Margin | -26.8 % |
| Operating Margin | -23.2 % |
| Return on Assets (ttm) | -9.1 % |
| Return on Equity (ttm) | -16.6 % |
| Qtrly Rev. Growth | -1.7 % |
| Gross Profit (p.s.) | 0.62 |
| Sales Per Share | 0.71 |
| EBITDA (p.s.) | -0.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -20.37 |
| PEG Ratio | 0 |
| Price to Book value | 3.42 |
| Price to Sales | 5.44 |
| Price to Cash Flow | -39.23 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|